MetaVia Reports Positive Phase 1b Clinical Trial Results for Obesity Drug DA-1726

summarizeSummary

MetaVia Inc. announced positive, statistically significant Phase 1b clinical trial results for its obesity drug DA-1726, showing robust weight loss, improved glucose control, and a favorable safety profile.

check_boxKey Events

• Positive Phase 1b Trial Results

  MetaVia announced statistically significant positive results from the 8-week, non-titrated 48 mg cohort of its Phase 1b clinical trial for DA-1726, a novel dual GLP1R/GCGR agonist for the treatment of obesity.

• Robust Weight Loss and Metabolic Improvements

  Patients achieved an average 9.1% weight reduction (21.2 lbs) and a statistically significant 9.8 cm reduction in waist circumference by Day 54. Fasted glucose improved by 12.3 mg/dL, and liver stiffness (VCTE) reduced by 23.7%.

• Favorable Safety Profile

  The trial reported no treatment-related discontinuations, with gastrointestinal events being mild to moderate in severity, indicating good tolerability for DA-1726.

• Differentiated Potential Highlighted

  CEO Hyung Heon Kim emphasized the drug's potential as a 'best-in-class treatment option' due to its compelling balance of weight loss, metabolic improvement, direct hepatic benefit, and tolerability.

auto_awesomeAnalysis

MetaVia Inc., a clinical-stage biotechnology company, announced highly encouraging Phase 1b clinical trial results for its obesity drug candidate, DA-1726. The data demonstrated statistically significant weight loss, improved glucose control, and notable reductions in liver stiffness, alongside a favorable safety profile. These positive outcomes for a dual GLP1R/GCGR agonist in a competitive market are a significant de-risking event for the company and could substantially enhance its valuation and future development prospects.